KIT and acute myeloid leukemia: In contrast, our previous findings after individualized treatment of a relapsed AML patient after SCT treated with Kit M indicated in vivo generated mature DCleu, activation of leukemia-specific effector and memory cells, downregulation of several checkpoint marker-expressing T and NK cells, and of Breg and Treg, along with a sustained clinical stabilization of the patient over 4 months [21].